PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings (NASDAQ:), Inc. (the Firm or Sonnet) (NASDAQ: SONN), a clinical-stage firm creating focused immunotherapeutic medication, right this moment introduced the subsequent CEO Nook phase has been printed on the Firm’s web site.
As a part of the CEO Nook phase, Pankaj Mohan, Ph.D., Founder and Chief Govt Officer of Sonnet, highlighted the Firm’s key accomplishments for calendar yr 2024 and the focused value-driving milestones in calendar yr 2025.
The CEO Nook is now accessible on the Firm’s web site right here. Segments on the CEO Nook platform can be accessible on the Firm’s web site (www.sonnetbio.com) for 90 days.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology firm with a proprietary platform for innovating biologic medication of single or bifunctional motion. Often called FHAB (Absolutely Human Albumin Binding), the expertise makes use of a completely human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to focus on tissues. Sonnet’s FHAB was designed to particularly goal tumor and lymphatic tissue, with an improved therapeutic window for optimizing the protection and efficacy of immune modulating biologic medication. FHAB is the inspiration of a modular, plug-and-play assemble for potentiating a spread of huge molecule therapeutic lessons, together with cytokines, peptides, antibodies, and vaccines.
Investor Relations Contact:
JTC Group, LLC
Jenene Thomas
908.824.0775
[email protected]
